EA008665B1 - Лекарственные средства для лечения хронического обструктивного заболевания лёгких - Google Patents

Лекарственные средства для лечения хронического обструктивного заболевания лёгких Download PDF

Info

Publication number
EA008665B1
EA008665B1 EA200500715A EA200500715A EA008665B1 EA 008665 B1 EA008665 B1 EA 008665B1 EA 200500715 A EA200500715 A EA 200500715A EA 200500715 A EA200500715 A EA 200500715A EA 008665 B1 EA008665 B1 EA 008665B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
hydrogen
compounds
methyl
general formula
Prior art date
Application number
EA200500715A
Other languages
English (en)
Russian (ru)
Other versions
EA200500715A1 (ru
Inventor
Тьерри Буассу
Франк Бютнер
Инго Конетцки
Забине Пестель
Андреас Шнапп
Германн Шолленберггер
Курт Шромм
Клаудиа Хайне
Клаус Рудольф
Филипп Лустенбергер
Кристоф Хёнке
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA008665(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200500715A1 publication Critical patent/EA200500715A1/ru
Publication of EA008665B1 publication Critical patent/EA008665B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200500715A 2002-11-15 2003-11-11 Лекарственные средства для лечения хронического обструктивного заболевания лёгких EA008665B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
EA200500715A1 EA200500715A1 (ru) 2005-12-29
EA008665B1 true EA008665B1 (ru) 2007-06-29

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500715A EA008665B1 (ru) 2002-11-15 2003-11-11 Лекарственные средства для лечения хронического обструктивного заболевания лёгких

Country Status (38)

Country Link
EP (2) EP1562603B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4317138B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101092247B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1713914A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR041969A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE430569T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003285326B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C016I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0316264B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2506082C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5570670A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110500T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10253282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1562603T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA008665B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP055774A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2326878T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20050432B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1400011I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL167900A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1562603I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92433I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00354B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05005081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300650I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO334314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ540661A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20040694A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL212238B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1562603E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS51607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1562603T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI343812B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA81276C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004045618A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200502246B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
AU2005235419B2 (en) * 2004-04-22 2010-11-04 Boehringer Ingelheim International Gmbh Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
EP1789394A1 (de) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP5270343B2 (ja) 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータミメティックスの製造方法
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Il13に対するヒト抗体および治療的使用
CN101296700A (zh) * 2005-11-09 2008-10-29 贝林格尔·英格海姆国际有限公司 吸入用气雾剂制剂
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンa2a受容体アゴニストとして使用するためのプリン誘導体
JP2010500319A (ja) * 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鏡像体上純粋な新規ベータアゴニスト、それらの製造方法及び医薬としてのそれらの使用
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
ATE493174T1 (de) 2007-01-10 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer
KR101456872B1 (ko) * 2007-01-25 2014-10-31 베링거 인겔하임 인터내셔날 게엠베하 베타미메틱의 제조방법
CA2685546A1 (en) 2007-05-07 2008-11-13 Novartis Ag Organic compounds
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
ES2442343T3 (es) 2008-12-30 2014-02-11 Pulmagen Therapeutics (Inflammation) Limited Compuestos de sulfonamida para el tratamiento de trastornos respiratorios
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP6084926B2 (ja) * 2010-09-21 2017-02-22 インテクリン・セラピユーテイクス・インコーポレイテツド 抗糖尿病固体医薬組成物
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PT3134395T (pt) 2014-04-24 2018-04-16 Novartis Ag Derivados de pirazina como inibidores de fosfatidilinositol 3-quinase
AU2014391608A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
DK3558954T3 (da) 2016-12-20 2021-12-06 Inke Sa Forbedret proces til fremstilling af r-6-hydroxy-8-[1-hydroxy-2-[2-(4methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110331A (pt) * 2000-04-27 2003-01-07 Boehringer Ingelheim Pharma Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
NO20052883L (no) 2005-06-14
FR14C0049I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-08-08
CN101817800A (zh) 2010-09-01
PT1562603E (pt) 2009-06-18
CY2014032I1 (el) 2015-12-09
EP1562603A2 (de) 2005-08-17
DK1562603T3 (da) 2009-09-07
PL375270A1 (en) 2005-11-28
PL212238B1 (pl) 2012-08-31
NO2014005I1 (no) 2014-03-10
BR0316264A (pt) 2005-10-11
ES2326878T3 (es) 2009-10-21
HUS1400011I1 (hu) 2022-02-28
ECSP055774A (es) 2005-11-22
DE10253282A1 (de) 2004-05-27
LU92433I2 (fr) 2014-06-24
ME00354B (me) 2011-10-10
TWI343812B (en) 2011-06-21
MY136034A (en) 2008-07-31
KR20050075013A (ko) 2005-07-19
LTC1562603I2 (lt) 2016-12-12
FR14C0049I2 (fr) 2015-07-24
CA2506082A1 (en) 2004-06-03
TW200423943A (en) 2004-11-16
CY1110500T1 (el) 2015-04-29
WO2004045618A2 (de) 2004-06-03
CO5570670A2 (es) 2005-10-31
AU2003285326B2 (en) 2009-06-04
DE50311502D1 (de) 2009-06-18
MEP53608A (en) 2011-05-10
IL167900A (en) 2013-06-27
BRPI0316264B1 (pt) 2019-04-09
WO2004045618A3 (de) 2004-09-30
AR041969A1 (es) 2005-06-01
NL300650I2 (nl) 2017-11-02
AR087241A2 (es) 2014-03-12
JP2006508140A (ja) 2006-03-09
NO334314B1 (no) 2014-02-03
HRP20050432B1 (en) 2012-01-31
BE2014C016I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
ATE430569T1 (de) 2009-05-15
MXPA05005081A (es) 2005-07-01
BRPI0316264B8 (pt) 2021-05-25
JP4317138B2 (ja) 2009-08-19
RS20050361A (sr) 2007-04-10
SI1562603T1 (sl) 2009-10-31
CN101735166A (zh) 2010-06-16
EP1562603B3 (de) 2014-01-08
EA200500715A1 (ru) 2005-12-29
ZA200502246B (en) 2006-01-25
NZ540661A (en) 2007-12-21
UA81276C2 (en) 2007-12-25
EP2025338A1 (de) 2009-02-18
CA2506082C (en) 2011-06-21
ES2326878T7 (es) 2014-03-11
RS51607B (sr) 2011-08-31
CY2014032I2 (el) 2015-12-09
PE20040694A1 (es) 2004-11-23
KR101092247B1 (ko) 2011-12-12
AU2003285326A1 (en) 2004-06-15
EP1562603B1 (de) 2009-05-06
HRP20050432A2 (en) 2006-06-30
CN1713914A (zh) 2005-12-28

Similar Documents

Publication Publication Date Title
EA008665B1 (ru) Лекарственные средства для лечения хронического обструктивного заболевания лёгких
US7056916B2 (en) Medicaments for the treatment of chronic obstructive pulmonary disease
JP5044221B2 (ja) 新規な長時間作用性ベータ−2−アゴニスト、及び薬物としての使用
US7135500B2 (en) Dihydroxymethylphenyl derivatives, processes for preparing them, and their use as pharmaceuticals
JP4682205B2 (ja) 呼吸器疾患の治療においてβ模倣薬として使用するためのヘテロアリール化合物
JP2007529443A (ja) 呼吸器疾患を治療するために持続性ベータ受容体刺激剤模倣薬として使用される新規ベンゾオキサジノン誘導体
EA012045B1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
JP4785751B2 (ja) 呼吸器疾患の治療のための3−ヒドロキシメチル−4−ヒドロキシ−フェニル誘導体
JP4950075B2 (ja) 呼吸器疾患の治療用の新規薬物
EA013157B1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
HK1144938A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
HK1144937A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
MXPA06007948A (es) Nuevos beta-2-agonistas de accion prolongada, y su uso como medicamentos
MXPA06010577A (en) Benzoxazine for treating respiratory tract diseases
HK1120030A (en) Novel drugs for treating respiratory diseases

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent